@CKD_ce Profile picture
Oct 18 26 tweets 34 min read
1) Welcome to this new #accredited #tweetorial on “Strategies to Apply Current Clinical Trial Data for SGLT2i to Reduce the Progression of CKD,” authored by our ⭐️tweetorialist Edgar V. Lerma 🇵🇭 @edgarvlermamd Image
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
3) Faculty disclosures and statement of accreditation are provided at ckd-ce.com/disclosures/. Please FOLLOW @ckd_ce (& @cardiomet_CE!) so you don't miss ANY of our unique serialized #tweetorials, always 🆓, always from expert authors! Prior programs at ckd-ce.com/category/dkd/ .
4) A case to start: 50♂️ with underlying type 2 diabetes (#T2D) and hypertension (#HTN) comes to your office for #CKD F/U. He has been diabetic for 20+ years and has #retinopathy and #neuropathy.
He is on amlodipine, chlorthalidone, glipizide, insulin, losartan, metformin.
5) Vital stats:
👉#UACR 1000 mg/g
👉#eGFR 31 mL/min/1.73 m2
👉BP 138/70
👉#A1C 7.6% (60 mmol/mol)
6) According to the @AmDiabetesAssn and @goKDIGO consensus, #SGLT2i are recommended in most patients with #T2D and #CKD with eGFR >/= 20 mL/min/1.73 m2 independent of HbA1c or the need for additional glucose lowering
👉 🔓pubmed.ncbi.nlm.nih.gov/36202661/ Image
7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with #T2D and CKD
#VisualAbstract by @brendonneuen @whatsthegfr

#CREDENCE 🔓pubmed.ncbi.nlm.nih.gov/30990260/

DAPA_CKD 🔓pubmed.ncbi.nlm.nih.gov/32970396/ ImageImage
8) These trials enrolled pts w/ #albuminuria:
#CREDENCE: ACR >/=300 mg/g
#DAPA_CKD: ACR >/=200 mg/g
& showed significant benefit for composite outcomes/EPs:
📌 Substantial eGFR ⬇️
📌 Kidney failure
📌 Mortality

CREDENCE pubmed.ncbi.nlm.nih.gov/30990260/
DAPA-CKD pubmed.ncbi.nlm.nih.gov/32970396/
9) Current evidence is strongest in this population, as emphasized by @AmDiabetesAssn recommendations
👉🔓 pubmed.ncbi.nlm.nih.gov/36202661/ Image
10) There is evidence from combined major #SGLT2i trials, however, suggesting that kidney and #CV benefits are consistent "irrespective of baseline #albuminuria"
👉🔓 pubmed.ncbi.nlm.nih.gov/31495651/
👉🔓 pubmed.ncbi.nlm.nih.gov/33222693/ ImageImage
11) This @JASN_News paper ➡️ relative effects of #canagliflozin on #renal & #CV outcomes are mostly consistent "across different levels of baseline albuminuria," but participants w/ severely increased #albuminuria saw the largest absolute benefits
👉🔓 pubmed.ncbi.nlm.nih.gov/31530577/ Image
12) The lower limit of #eGFR for which initiation of #SGLT2i is recommended has changed over time as new data have rapidly become available
13) The @goKDIGO 2022 guideline recommended initiation of an #SGLT2i for patients with #T2D and #CKD who have #eGFR >/= 20 (a change from >/= 30 in the 2020 guideline)
👉🔓 pubmed.ncbi.nlm.nih.gov/36202661/
14) The @AmDiabetesAssn has also updated this threshold to >/= 20 in its living Standards of Care (from >/= 25 in the initial issue of the 2022 Standards of Care)
👉🔓 pubmed.ncbi.nlm.nih.gov/36202661/
15) These changes are driven largely by findings of new trials, including the #DAPA_CKD trial (which provided clear evidence of efficacy and safety for #dapagliflozin in patients with #eGFR >/= 25 and #ACR >/= 200 mg/g)
DAPA-CKD: 🔓pubmed.ncbi.nlm.nih.gov/32970396/ Image
16) #Empagliflozin Outcome Trials in Patients w/ Chronic HF (EMPEROR) provided clear evidence of efficacy & safety for empa in patients w/ #eGFR >/= 20 & HF
#VisualAbstract by @whatsthegfr
#EMPEROR_Preserved 🔓pubmed.ncbi.nlm.nih.gov/34449189/
#EMPEROR_Reduced 🔓pubmed.ncbi.nlm.nih.gov/32865377/ Image
17) Additional support comes from subgroup analyses of participants in the #CREDENCE and #DAPA_CKD trials with baseline eGFR <30
#VisualAbstract by @divyaa24

👉 @CJASN 🔓 pubmed.ncbi.nlm.nih.gov/33214158/
👉 @JASN_News 🔓pubmed.ncbi.nlm.nih.gov/34272327/ Image
18) Evidence supporting initiation of an #SGLT2i for patients with #T2D and #eGFR 20–29 mL/min/1.73 m2 is strongest for patients with concomitant #albuminuria or #HF
👉 🔓pubmed.ncbi.nlm.nih.gov/34272327/
👉 🔓pubmed.ncbi.nlm.nih.gov/33214158/
👉 🔓pubmed.ncbi.nlm.nih.gov/31495651/ ImageImage
19) #SGLT2i have been observed to have consistent efficacy and safety across studied ranges of #eGFR
👉 pubmed.ncbi.nlm.nih.gov/31495651/ ImageImage
20) See the areas of overlap for clinical trials with #SGLT2i in patients with #CKD
👉 🔓pubmed.ncbi.nlm.nih.gov/31727290/ ImageImage
21) On the background of these trials, according to the @AmDiabetesAssn and @goKDIGO consensus, an #SGLT2i can be initiated for most patients with #T2D, #CKD, and #eGFR >/=20 ImageImage
22) In the much anticipated EMPA-KIDNEY trial (The Study of Heart & Kidney Protection w/Empagliflozin), entry criteria were expanded to include nonalbuminuric CKD with an eGFR initiation threshold >/= 20 among >6,600 participants +/- T2D
👉 @NDTsocial 🔓pubmed.ncbi.nlm.nih.gov/35238940/ Image
23) Like #CREDENCE and #DAPA_CKD, #EMPA_KIDNEY was stopped early for clear positive #efficacy
👉 boehringer-ingelheim.com/human-health/m… Image
24a) So let's pause here for a knowledge check, knowing that @nephondemand @ChristosArgyrop @Sglt2inhibitorL @HecmagsMD @sophia_kidney all know the answer . . .
#FOAMed #NephTwitter @MedTweetorials
24b) In 2022, both @goKDIGO and @AmDiabetesAssn updated its threshold for initiating @Sglt2I in patients with #T2D to eGFR down to 20. Benefit at this lower level is most pronounced in patients with
25) Mark your response and RETURN TOMORROW for the correct answer and the remainder of this #tweetorial so that you can grab your 0.5hr 🆓CE/#CME! See you then!!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with @CKD_ce

@CKD_ce Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ckd_ce

Sep 13
1) Welcome to a new #accredited (0.75h CE/#CME) #tweetorial on challenging case presentations for pts with #cardiometabolic disease, #CaReMe #FOAMed.
Our expert author is Claire Davies. @claireyrivs is a specialist diabetes & endocrinology #pharmacist working in Gateshead in 🇬🇧. Image
2) She is a member of UKCPA Diabetes & Endocrinology committee @UKCPADiabetes & works across #diabetes, #endocrinology, & emergency/acute care in Secondary Care. She is currently involved in development of regional guidelines & education to support medicines optimisation for PLWD
3a) This program is intended for healthcare professionals and is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company.
Read 36 tweets
Sep 7
1) Welcome to our new #accredited #tweetorial on the Pathophysiology of #DKD in #T2D: Traditional Teaching and New Insights. Our expert author is Hans-Joachim Anders, MD, @hjanders_hans from @LMU_Uniklinikum of @LMU_Muenchen
2) This #accredited #tweetorial series on the foundations of #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures & accreditation statement are at ckd-ce.com/disclosures/. FOLLOW US!
Read 48 tweets
Aug 23
1a) Welcome to one of our favorite events on the @academiccme #accredited #tweetorial feeds: a takeover of our programming from @GoggleDocs! The focus of this tweetorial is data from #ADA2022 on #SGLT2i beyond cardiac disease. Our expert author is @GoggleDocs' @drpatrickholmes. Image
1b) Check out our other #ADA2022 recap #tweetorial by new @GoggleDocs family member @Ines_VFonseca who focused on the cardiac data presented: ckd-ce.com/dkd13_ada22a/
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
Read 59 tweets
Aug 3
1) Welcome to our new #accredited #tweetorial which is Part 2 of a 2-part "highlights" program on new #SGLT2i & #DKD data presented at @ERAkidney #ERA22. #Physicians #nurses #pharmacists #PAs and #NPs can all earn 0.5h CE/#CME by following this 🧵!
2a) @ERAkidney #ERA22 is a primary international scientific symposium for interaction and exchange among basic scientists and clinicians working in #Nephrology. Our expert author is Dr. Clara García Carro (@ClaraGCarro) from San Carlos Clinical Hospital (Madrid, Spain).
2b) Be sure to check out the first half of this #ERA22 recap from my colleague @shbermejo, and get MORE 🆓CE/#CME at ckd-ce.com/dkd12_ERA22a/. Join me in following @ckd_ce for the BEST in #cardiorenal education delivered entirely by #tweetorial!
Read 48 tweets
Jul 26
1) Welcome to our new #accredited #tweetorial which is Part 1 of a 2-part "highlights" program on new #SGLT2i & #DKD data presented at @ERAkidney #ERA22. #Physicians #nurses #pharmacists #PAs and #NPs can all earn 0.5h CE/#CME by following this thread!
2) @ERAkidney #ERA22 is a primary international scientific symposium for interaction and exchange among basic scientists and clinicians working in #Nephrology. It was held in May. Our expert author is Dr. Sheila Bermejo (@shbermejo) from @vallhebron in Barcelona, Spain.
3) This program is #accredited for CE/#CME & is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US- or UK-based based HCPs. Accreditation statement & faculty disclosures at ckd-ce.com/disclosures/.
Read 43 tweets
Jul 7
1) Welcome to a new #accredited #tweetorial on optimizing the role of the pharmacist in managing cardiometabolic disease! Accredited for 0.50 hr for #physicians #nurses #pharmacists! Expert faculty is Snehal Bhatt PharmD @SnayCardsPharmD of @BIDMChealth. Image
2a) This educational activity is supported by grants from Bayer, Otsuka, & Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company. See archived programs, all by expert authors, still available for credit at ckd-ce.com.
2b) Accreditation statement and faculty disclosures are at ckd-ce.com/disclosures/. We are your ONLY source for accredited education in CKD and #cardiorenal disease delivered wholly on Twitter. FOLLOW US!
Read 24 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(